Abbreviated Prescribing Information

bicaVera 1.5 % Glucose, 1.75 mmol/l Calcium, Solution for peritoneal dialysis
bicaVera 2.3 % Glucose, 1.75 mmol/l Calcium, Solution for peritoneal dialysis
bicaVera 4.25 % Glucose, 1.75 mmol/l Calcium, Solution for peritoneal dialysis
bicaVera 1.5 % Glucose, 1.25 mmol/l Calcium, Solution for peritoneal dialysis
bicaVera 2.3 % Glucose, 1.25 mmol/l Calcium, Solution for peritoneal dialysis
bicaVera 4.25 % Glucose, 1.25 mmol/l Calcium, Solution for peritoneal dialysis

These solutions are delivered in a double chamber bag. One chamber contains the alkaline hydrogen carbonate solution, the other chamber contains the acidic glucose-based electrolyte solution. Mixing of both solutions by opening the median seam between the two chambers results in the ready-to-use solution.

Composition:

1 litre of the ready-to-use solution contains:

bicaVera 1.5 % Glucose, 1.75 mmol/l Calcium: calcium chloride dihydrate 0.2573 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 16.5 g (glucose 15.0 g)

bicaVera 2.3 % Glucose, 1.75 mmol/l Calcium: calcium chloride dihydrate 0.2573 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 25.0 g (glucose 22.73 g)

bicaVera 4.25 % Glucose, 1.75 mmol/l Calcium: calcium chloride dihydrate 0.2573 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 46.75 g (glucose 42.5 g)

bicaVera 1.5 % Glucose, 1.25 mmol/l Calcium: calcium chloride dihydrate 0.1838 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 16.5 g (glucose 15.0 g)

bicaVera 2.3 % Glucose, 1.25 mmol/l Calcium: calcium chloride dihydrate 0.1838 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 25.0 g (glucose 22.73 g)

bicaVera 4.25 % Glucose, 1.25 mmol/l Calcium: calcium chloride dihydrate 0.1838 g, sodium chloride 5.786 g, sodium hydrogen carbonate 2.940 g, magnesium chloride hexahydrate 0.1017 g, glucose monohydrate 46.75 g (glucose 42.5 g)

Excipients

Hydrochloric acid, sodium hydroxide, carbon dioxide, water for injections

Indications:

End-stage (decompensated) chronic renal failure of any origin treated with peritoneal dialysis.

Contraindications:

Solution specific:
Solutions with 1.75 mmol/l calcium: Severe hypokalaemia and severe hypercalcaemia.
Solutions with 1.25 mmol/l calcium: Severe hypokalaemia and severe hypocalcaemia.
Solutions with 2.3%/4.25% glucose: additionally hypovolaemia and arterial hypotension.

Treatment related:
Recent abdominal surgery or injury, history of abdominal operations with fibrous adhesions, severe abdominal burns, bowel perforation; extensive inflammatory conditions of the abdominal skin (dermatitis); inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticulitis); localized peritonitis; abdominal fistula; hernia; intra-abdominal tumours; ileus; pulmonary disease (especially pneumonia); sepsis; extreme hyperlipidaemia; rare cases of uraemia, which cannot be managed by peritoneal dialysis; cachexia and severe weight loss, particularly in cases where ingestion of adequate protein is not guaranteed; physical or mental disability to perform peritoneal dialysis.
Undesirable effects

Solution specific:
Electrolyte disturbances, e.g. hypokalaemia, additionally hypocalcaemia for solutions containing 1.25 mmol/l calcium respectively hypercalcaemia in combination with an increased calcium uptake for solutions containing 1.75 mmol/l calcium; disturbances in hydration, e.g. dehydration, indicated by a rapid decrease in body weight, hypotension, dizziness and/or tachycardia, or overhydration indicated by a rapid increase in body weight, oedema, hypertension and/or dyspnœa; increased blood sugar levels; hyperlipidaemia; increase in body weight due to the continuous uptake of glucose from the peritoneal dialysis solution. Secondary hyperparathyroidism with potential disturbances of the bone metabolism for solutions containing 1.25 mmol/l calcium.

Treatment related:
Peritonitis, indicated by cloudy effluent, later abdominal pain, fever, and general malaise or, in very rare cases, sepsis; skin exit site or tunnel infection of the catheter indicated by redness, oedema, pain, exudations or crusts; in- and outflow disturbances of the dialysis solution, diarrhoea or constipation, encapsulating peritoneal sclerosis; dyspnœa caused by the elevated diaphragm; hernia; abdominal distension and sensation of fullness; shoulder pain.

Possibly bicaVera or not all strengths of bicaVera are registered or marketed in your country.
Prescription only medicine.

Date: December 2019

Fresenius Medical Care Deutschland GmbH
Else-Kröner-Straße 1, 61352 Bad Homburg v.d.H., Germany